APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gefitinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gefitinib Market Outlook and Growth Opportunities 2026

23 December 2025206 pages

Choose your research edition.

Industry ResearchGefitinib Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Gefitinib Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Gefitinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gefitinib Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gefitinib Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Gefitinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gefitinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gefitinib market include Qilu Pharmaceutical, AstraZeneca, Zuventus Healthcare, United Biotech, Sichuan Xieli Pharmaceutical, Panacea Biotec, Nobel Ilac Sanayii Ve Ticaret, Nishchay Pharmaceuticals and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gefitinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gefitinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gefitinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gefitinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Gefitinib Segment by Company

Qilu Pharmaceutical

AstraZeneca

Zuventus Healthcare

United Biotech

Sichuan Xieli Pharmaceutical

Panacea Biotec

Nobel Ilac Sanayii Ve Ticaret

Nishchay Pharmaceuticals

Natco Pharma

Jodas Expoim

Hetero Drugs

Globela Pharma

Glenmark Pharmaceuticals

Flagship Biotech International

Ethypharm

Dr Reddy's Laboratories

Cipla

Celon Laboratories

Cadila Pharmaceuticals

Accure Labs

Gefitinib Segment by Type

10 Tables/Box

30 Tables/Box

90 Tables/Box

Gefitinib Segment by Application

Drug Center

Hospital

Clinic

Others

Gefitinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gefitinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gefitinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gefitinib significant trends, drivers, influence factors in global and regions.

6. To analyze Gefitinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gefitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gefitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gefitinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gefitinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gefitinib industry.

Chapter 3: Detailed analysis of Gefitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gefitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gefitinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gefitinib Industry Trends Table 2. Gefitinib Industry Drivers Table 3. Gefitinib Industry Opportunities and Challenges Table 4. Gefitinib Industry Restraints Table 5. Global Gefitinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gefitinib Revenue Share by Company (2021-2026) Table 7. Global Gefitinib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Gefitinib Sales Volume Share by Company (2021-2026) Table 9. Global Gefitinib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Gefitinib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gefitinib Key Company Manufacturing Base & Headquarters Table 12. Global Gefitinib Company, Product Type & Application Table 13. Global Gefitinib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gefitinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10 Tables/Box Table 18. Significant Companies of 30 Tables/Box Table 19. Significant Companies of 90 Tables/Box Table 20. Global Gefitinib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 21. Global Gefitinib Sales Volume by Type (2021-2026) & (k pcs) Table 22. Global Gefitinib Sales Volume by Type (2027-2032) & (k pcs) Table 23. Global Gefitinib Sales Volume Share by Type (2021-2026) Table 24. Global Gefitinib Sales Volume Share by Type (2027-2032) Table 25. Global Gefitinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gefitinib Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Gefitinib Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Gefitinib Sales Value Share by Type (2021-2026) Table 29. Global Gefitinib Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Drug Center Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Gefitinib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 35. Global Gefitinib Sales Volume by Application (2021-2026) & (k pcs) Table 36. Global Gefitinib Sales Volume by Application (2027-2032) & (k pcs) Table 37. Global Gefitinib Sales Volume Share by Application (2021-2026) Table 38. Global Gefitinib Sales Volume Share by Application (2027-2032) Table 39. Global Gefitinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Gefitinib Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Gefitinib Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Gefitinib Sales Value Share by Application (2021-2026) Table 43. Global Gefitinib Sales Value Share by Application (2027-2032) Table 44. Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 45. Global Gefitinib Sales by Region (2021-2026) & (k pcs) Table 46. Global Gefitinib Sales Market Share by Region (2021-2026) Table 47. Global Gefitinib Sales by Region (2027-2032) & (k pcs) Table 48. Global Gefitinib Sales Market Share by Region (2027-2032) Table 49. Global Gefitinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Gefitinib Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Gefitinib Sales Value Share by Region (2021-2026) Table 52. Global Gefitinib Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Gefitinib Sales Value Share by Region (2027-2032) Table 54. Global Gefitinib Market Average Price (US$/pcs) by Region (2021-2026) Table 55. Global Gefitinib Market Average Price (US$/pcs) by Region (2027-2032) Table 56. Global Gefitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. Global Gefitinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Gefitinib Sales by Country (2021-2026) & (k pcs) Table 59. Global Gefitinib Sales Market Share by Country (2021-2026) Table 60. Global Gefitinib Sales by Country (2027-2032) & (k pcs) Table 61. Global Gefitinib Sales Market Share by Country (2027-2032) Table 62. Global Gefitinib Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Gefitinib Sales Value Market Share by Country (2021-2026) Table 64. Global Gefitinib Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Gefitinib Sales Value Market Share by Country (2027-2032) Table 66. Qilu Pharmaceutical Company Information Table 67. Qilu Pharmaceutical Business Overview Table 68. Qilu Pharmaceutical Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 69. Qilu Pharmaceutical Gefitinib Product Portfolio Table 70. Qilu Pharmaceutical Recent Development Table 71. AstraZeneca Company Information Table 72. AstraZeneca Business Overview Table 73. AstraZeneca Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. AstraZeneca Gefitinib Product Portfolio Table 75. AstraZeneca Recent Development Table 76. Zuventus Healthcare Company Information Table 77. Zuventus Healthcare Business Overview Table 78. Zuventus Healthcare Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 79. Zuventus Healthcare Gefitinib Product Portfolio Table 80. Zuventus Healthcare Recent Development Table 81. United Biotech Company Information Table 82. United Biotech Business Overview Table 83. United Biotech Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 84. United Biotech Gefitinib Product Portfolio Table 85. United Biotech Recent Development Table 86. Sichuan Xieli Pharmaceutical Company Information Table 87. Sichuan Xieli Pharmaceutical Business Overview Table 88. Sichuan Xieli Pharmaceutical Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 89. Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio Table 90. Sichuan Xieli Pharmaceutical Recent Development Table 91. Panacea Biotec Company Information Table 92. Panacea Biotec Business Overview Table 93. Panacea Biotec Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 94. Panacea Biotec Gefitinib Product Portfolio Table 95. Panacea Biotec Recent Development Table 96. Nobel Ilac Sanayii Ve Ticaret Company Information Table 97. Nobel Ilac Sanayii Ve Ticaret Business Overview Table 98. Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 99. Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio Table 100. Nobel Ilac Sanayii Ve Ticaret Recent Development Table 101. Nishchay Pharmaceuticals Company Information Table 102. Nishchay Pharmaceuticals Business Overview Table 103. Nishchay Pharmaceuticals Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 104. Nishchay Pharmaceuticals Gefitinib Product Portfolio Table 105. Nishchay Pharmaceuticals Recent Development Table 106. Natco Pharma Company Information Table 107. Natco Pharma Business Overview Table 108. Natco Pharma Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 109. Natco Pharma Gefitinib Product Portfolio Table 110. Natco Pharma Recent Development Table 111. Jodas Expoim Company Information Table 112. Jodas Expoim Business Overview Table 113. Jodas Expoim Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 114. Jodas Expoim Gefitinib Product Portfolio Table 115. Jodas Expoim Recent Development Table 116. Hetero Drugs Company Information Table 117. Hetero Drugs Business Overview Table 118. Hetero Drugs Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 119. Hetero Drugs Gefitinib Product Portfolio Table 120. Hetero Drugs Recent Development Table 121. Globela Pharma Company Information Table 122. Globela Pharma Business Overview Table 123. Globela Pharma Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 124. Globela Pharma Gefitinib Product Portfolio Table 125. Globela Pharma Recent Development Table 126. Glenmark Pharmaceuticals Company Information Table 127. Glenmark Pharmaceuticals Business Overview Table 128. Glenmark Pharmaceuticals Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 129. Glenmark Pharmaceuticals Gefitinib Product Portfolio Table 130. Glenmark Pharmaceuticals Recent Development Table 131. Flagship Biotech International Company Information Table 132. Flagship Biotech International Business Overview Table 133. Flagship Biotech International Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 134. Flagship Biotech International Gefitinib Product Portfolio Table 135. Flagship Biotech International Recent Development Table 136. Ethypharm Company Information Table 137. Ethypharm Business Overview Table 138. Ethypharm Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 139. Ethypharm Gefitinib Product Portfolio Table 140. Ethypharm Recent Development Table 141. Dr Reddy's Laboratories Company Information Table 142. Dr Reddy's Laboratories Business Overview Table 143. Dr Reddy's Laboratories Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 144. Dr Reddy's Laboratories Gefitinib Product Portfolio Table 145. Dr Reddy's Laboratories Recent Development Table 146. Cipla Company Information Table 147. Cipla Business Overview Table 148. Cipla Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 149. Cipla Gefitinib Product Portfolio Table 150. Cipla Recent Development Table 151. Celon Laboratories Company Information Table 152. Celon Laboratories Business Overview Table 153. Celon Laboratories Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 154. Celon Laboratories Gefitinib Product Portfolio Table 155. Celon Laboratories Recent Development Table 156. Cadila Pharmaceuticals Company Information Table 157. Cadila Pharmaceuticals Business Overview Table 158. Cadila Pharmaceuticals Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 159. Cadila Pharmaceuticals Gefitinib Product Portfolio Table 160. Cadila Pharmaceuticals Recent Development Table 161. Accure Labs Company Information Table 162. Accure Labs Business Overview Table 163. Accure Labs Gefitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 164. Accure Labs Gefitinib Product Portfolio Table 165. Accure Labs Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Gefitinib Distributors List Table 169. Gefitinib Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Gefitinib Product Image Figure 2. Global Gefitinib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gefitinib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gefitinib Sales (2021-2032) & (k pcs) Figure 5. Global Gefitinib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Gefitinib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10 Tables/Box Image Figure 10. 30 Tables/Box Image Figure 11. 90 Tables/Box Image Figure 12. Global Gefitinib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 13. Global Gefitinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Gefitinib Sales Volume Share by Type (2021-2032) Figure 15. Global Gefitinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gefitinib Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gefitinib Sales Value Share by Type (2021-2032) Figure 18. Drug Center Image Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Gefitinib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 23. Global Gefitinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Gefitinib Sales Volume Share by Application (2021-2032) Figure 25. Global Gefitinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Gefitinib Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Gefitinib Sales Value Share by Application (2021-2032) Figure 28. Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 29. Global Gefitinib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Gefitinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Gefitinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Gefitinib Sales Value (2021-2032) & (US$ Million) Figure 33. North America Gefitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Gefitinib Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Gefitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Gefitinib Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Gefitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Gefitinib Sales Value (2021-2032) & (US$ Million) Figure 39. South America Gefitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Gefitinib Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Gefitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Gefitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Gefitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Gefitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Gefitinib Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Gefitinib Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 10 Tables/Box
  • 30 Tables/Box
  • 90 Tables/Box
Applications
  • Drug Center
  • Hospital
  • Clinic
  • Others
Companies covered
  • Qilu Pharmaceutical
  • AstraZeneca
  • Zuventus Healthcare
  • United Biotech
  • Sichuan Xieli Pharmaceutical
  • Panacea Biotec
  • Nobel Ilac Sanayii Ve Ticaret
  • Nishchay Pharmaceuticals
  • Natco Pharma
  • Jodas Expoim
  • Hetero Drugs
  • Globela Pharma
  • Glenmark Pharmaceuticals
  • Flagship Biotech International
  • Ethypharm
  • Dr Reddy's Laboratories
  • Cipla
  • Celon Laboratories
  • Cadila Pharmaceuticals
  • Accure Labs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gefitinib Sales Value (2021-2032)
  4. 1.2.2 Global Gefitinib Sales Volume (2021-2032)
  5. 1.2.3 Global Gefitinib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gefitinib Market Dynamics
  1. 2.1 Gefitinib Industry Trends
  2. 2.2 Gefitinib Industry Drivers
  3. 2.3 Gefitinib Industry Opportunities and Challenges
  4. 2.4 Gefitinib Industry Restraints
3 Gefitinib Market by Company
  1. 3.1 Global Gefitinib Company Revenue Ranking in 2025
  2. 3.2 Global Gefitinib Revenue by Company (2021-2026)
  3. 3.3 Global Gefitinib Sales Volume by Company (2021-2026)
  4. 3.4 Global Gefitinib Average Price by Company (2021-2026)
  5. 3.5 Global Gefitinib Company Ranking (2024-2026)
  6. 3.6 Global Gefitinib Company Manufacturing Base and Headquarters
  7. 3.7 Global Gefitinib Company Product Type and Application
  8. 3.8 Global Gefitinib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gefitinib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gefitinib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gefitinib Market by Type
  1. 4.1 Gefitinib Type Introduction
  2. 4.1.1 10 Tables/Box
  3. 4.1.2 30 Tables/Box
  4. 4.1.3 90 Tables/Box
  5. 4.2 Global Gefitinib Sales Volume by Type
  6. 4.2.1 Global Gefitinib Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gefitinib Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Gefitinib Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Gefitinib Sales Value by Type
  10. 4.3.1 Global Gefitinib Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gefitinib Sales Value by Type (2021-2032)
  12. 4.3.3 Global Gefitinib Sales Value Share by Type (2021-2032)
5 Gefitinib Market by Application
  1. 5.1 Gefitinib Application Introduction
  2. 5.1.1 Drug Center
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Gefitinib Sales Volume by Application
  7. 5.2.1 Global Gefitinib Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gefitinib Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Gefitinib Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Gefitinib Sales Value by Application
  11. 5.3.1 Global Gefitinib Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gefitinib Sales Value by Application (2021-2032)
  13. 5.3.3 Global Gefitinib Sales Value Share by Application (2021-2032)
6 Gefitinib Regional Sales and Value Analysis
  1. 6.1 Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gefitinib Sales by Region (2021-2032)
  3. 6.2.1 Global Gefitinib Sales by Region: 2021-2026
  4. 6.2.2 Global Gefitinib Sales by Region (2027-2032)
  5. 6.3 Global Gefitinib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gefitinib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gefitinib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gefitinib Sales Value by Region (2027-2032)
  9. 6.5 Global Gefitinib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gefitinib Sales Value (2021-2032)
  12. 6.6.2 North America Gefitinib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gefitinib Sales Value (2021-2032)
  15. 6.7.2 Europe Gefitinib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gefitinib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gefitinib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gefitinib Sales Value (2021-2032)
  21. 6.9.2 South America Gefitinib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gefitinib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gefitinib Sales Value Share by Country, 2025 VS 2032
7 Gefitinib Country-level Sales and Value Analysis
  1. 7.1 Global Gefitinib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gefitinib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gefitinib Sales by Country (2021-2032)
  4. 7.3.1 Global Gefitinib Sales by Country (2021-2026)
  5. 7.3.2 Global Gefitinib Sales by Country (2027-2032)
  6. 7.4 Global Gefitinib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gefitinib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gefitinib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gefitinib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gefitinib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gefitinib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gefitinib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gefitinib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gefitinib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gefitinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gefitinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gefitinib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gefitinib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gefitinib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gefitinib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gefitinib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gefitinib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gefitinib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gefitinib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gefitinib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gefitinib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gefitinib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gefitinib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gefitinib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gefitinib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gefitinib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gefitinib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gefitinib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gefitinib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gefitinib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gefitinib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gefitinib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gefitinib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gefitinib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gefitinib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gefitinib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gefitinib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gefitinib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gefitinib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gefitinib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gefitinib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gefitinib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gefitinib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gefitinib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gefitinib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gefitinib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gefitinib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gefitinib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gefitinib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gefitinib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gefitinib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gefitinib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gefitinib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gefitinib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gefitinib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gefitinib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gefitinib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gefitinib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gefitinib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gefitinib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gefitinib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gefitinib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gefitinib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gefitinib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gefitinib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gefitinib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gefitinib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gefitinib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gefitinib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gefitinib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gefitinib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gefitinib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gefitinib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gefitinib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gefitinib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gefitinib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gefitinib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gefitinib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gefitinib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gefitinib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gefitinib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gefitinib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gefitinib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gefitinib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gefitinib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gefitinib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gefitinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Qilu Pharmaceutical
  2. 8.1.1 Qilu Pharmaceutical Company Information
  3. 8.1.2 Qilu Pharmaceutical Business Overview
  4. 8.1.3 Qilu Pharmaceutical Gefitinib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Qilu Pharmaceutical Gefitinib Product Portfolio
  6. 8.1.5 Qilu Pharmaceutical Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Gefitinib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Gefitinib Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Zuventus Healthcare
  14. 8.3.1 Zuventus Healthcare Company Information
  15. 8.3.2 Zuventus Healthcare Business Overview
  16. 8.3.3 Zuventus Healthcare Gefitinib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zuventus Healthcare Gefitinib Product Portfolio
  18. 8.3.5 Zuventus Healthcare Recent Developments
  19. 8.4 United Biotech
  20. 8.4.1 United Biotech Company Information
  21. 8.4.2 United Biotech Business Overview
  22. 8.4.3 United Biotech Gefitinib Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 United Biotech Gefitinib Product Portfolio
  24. 8.4.5 United Biotech Recent Developments
  25. 8.5 Sichuan Xieli Pharmaceutical
  26. 8.5.1 Sichuan Xieli Pharmaceutical Company Information
  27. 8.5.2 Sichuan Xieli Pharmaceutical Business Overview
  28. 8.5.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio
  30. 8.5.5 Sichuan Xieli Pharmaceutical Recent Developments
  31. 8.6 Panacea Biotec
  32. 8.6.1 Panacea Biotec Company Information
  33. 8.6.2 Panacea Biotec Business Overview
  34. 8.6.3 Panacea Biotec Gefitinib Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Panacea Biotec Gefitinib Product Portfolio
  36. 8.6.5 Panacea Biotec Recent Developments
  37. 8.7 Nobel Ilac Sanayii Ve Ticaret
  38. 8.7.1 Nobel Ilac Sanayii Ve Ticaret Company Information
  39. 8.7.2 Nobel Ilac Sanayii Ve Ticaret Business Overview
  40. 8.7.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio
  42. 8.7.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
  43. 8.8 Nishchay Pharmaceuticals
  44. 8.8.1 Nishchay Pharmaceuticals Company Information
  45. 8.8.2 Nishchay Pharmaceuticals Business Overview
  46. 8.8.3 Nishchay Pharmaceuticals Gefitinib Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Nishchay Pharmaceuticals Gefitinib Product Portfolio
  48. 8.8.5 Nishchay Pharmaceuticals Recent Developments
  49. 8.9 Natco Pharma
  50. 8.9.1 Natco Pharma Company Information
  51. 8.9.2 Natco Pharma Business Overview
  52. 8.9.3 Natco Pharma Gefitinib Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Natco Pharma Gefitinib Product Portfolio
  54. 8.9.5 Natco Pharma Recent Developments
  55. 8.10 Jodas Expoim
  56. 8.10.1 Jodas Expoim Company Information
  57. 8.10.2 Jodas Expoim Business Overview
  58. 8.10.3 Jodas Expoim Gefitinib Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jodas Expoim Gefitinib Product Portfolio
  60. 8.10.5 Jodas Expoim Recent Developments
  61. 8.11 Hetero Drugs
  62. 8.11.1 Hetero Drugs Company Information
  63. 8.11.2 Hetero Drugs Business Overview
  64. 8.11.3 Hetero Drugs Gefitinib Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hetero Drugs Gefitinib Product Portfolio
  66. 8.11.5 Hetero Drugs Recent Developments
  67. 8.12 Globela Pharma
  68. 8.12.1 Globela Pharma Company Information
  69. 8.12.2 Globela Pharma Business Overview
  70. 8.12.3 Globela Pharma Gefitinib Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Globela Pharma Gefitinib Product Portfolio
  72. 8.12.5 Globela Pharma Recent Developments
  73. 8.13 Glenmark Pharmaceuticals
  74. 8.13.1 Glenmark Pharmaceuticals Company Information
  75. 8.13.2 Glenmark Pharmaceuticals Business Overview
  76. 8.13.3 Glenmark Pharmaceuticals Gefitinib Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Glenmark Pharmaceuticals Gefitinib Product Portfolio
  78. 8.13.5 Glenmark Pharmaceuticals Recent Developments
  79. 8.14 Flagship Biotech International
  80. 8.14.1 Flagship Biotech International Company Information
  81. 8.14.2 Flagship Biotech International Business Overview
  82. 8.14.3 Flagship Biotech International Gefitinib Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Flagship Biotech International Gefitinib Product Portfolio
  84. 8.14.5 Flagship Biotech International Recent Developments
  85. 8.15 Ethypharm
  86. 8.15.1 Ethypharm Company Information
  87. 8.15.2 Ethypharm Business Overview
  88. 8.15.3 Ethypharm Gefitinib Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Ethypharm Gefitinib Product Portfolio
  90. 8.15.5 Ethypharm Recent Developments
  91. 8.16 Dr Reddy's Laboratories
  92. 8.16.1 Dr Reddy's Laboratories Company Information
  93. 8.16.2 Dr Reddy's Laboratories Business Overview
  94. 8.16.3 Dr Reddy's Laboratories Gefitinib Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Dr Reddy's Laboratories Gefitinib Product Portfolio
  96. 8.16.5 Dr Reddy's Laboratories Recent Developments
  97. 8.17 Cipla
  98. 8.17.1 Cipla Company Information
  99. 8.17.2 Cipla Business Overview
  100. 8.17.3 Cipla Gefitinib Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Cipla Gefitinib Product Portfolio
  102. 8.17.5 Cipla Recent Developments
  103. 8.18 Celon Laboratories
  104. 8.18.1 Celon Laboratories Company Information
  105. 8.18.2 Celon Laboratories Business Overview
  106. 8.18.3 Celon Laboratories Gefitinib Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Celon Laboratories Gefitinib Product Portfolio
  108. 8.18.5 Celon Laboratories Recent Developments
  109. 8.19 Cadila Pharmaceuticals
  110. 8.19.1 Cadila Pharmaceuticals Company Information
  111. 8.19.2 Cadila Pharmaceuticals Business Overview
  112. 8.19.3 Cadila Pharmaceuticals Gefitinib Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Cadila Pharmaceuticals Gefitinib Product Portfolio
  114. 8.19.5 Cadila Pharmaceuticals Recent Developments
  115. 8.20 Accure Labs
  116. 8.20.1 Accure Labs Company Information
  117. 8.20.2 Accure Labs Business Overview
  118. 8.20.3 Accure Labs Gefitinib Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Accure Labs Gefitinib Product Portfolio
  120. 8.20.5 Accure Labs Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gefitinib Value Chain Analysis
  2. 9.1.1 Gefitinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gefitinib Sales Mode & Process
  6. 9.2 Gefitinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gefitinib Distributors
  9. 9.2.3 Gefitinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst